1/17/20 SHR # 2455 : Cibinetide (ARA 290) This Groundbreaking Peptide Can Treat Neuropathy, Neuralgia & Fibromyalgia

By Elizabeth F. Yurth, MD | Peptides

Mar 28

The National Institute of Health estimates over 20 million people suffer from peripheral neuropathy. They also acknowledge that this number may be highly under-represented since there a other forms of neuropathy that don’t cause pain. Add to that only recently it was shown that Fibromyalgia has a neuropathy and small fiber nerve damage component so add to that another 12 million – almost all women. The most insidious type of nerve degradation that rarely gets reported due to lack of pain attacks the organs in the body. Remove the nerve impulses from the heart, liver, pancreas or brain and slowly your body begins to fail. Most neuropathies are treated with drugs like Cymbalta in an attempt to mitigate the pain. They often don’t work and carry horrible unwanted effects. The peptide Cibinetide (ARA 290)  looks to be the first thing that addresses the problem by fixing and repairing the nerves as opposed to masking the symptoms.

Listen to the Podcast here.

Call 303-443-0848

Questions About Peptides?

Boulder Longevity Institute is home to the nation's 1st Medically Managed Peptide Program for Human Optimization. If you're interested in learning more, give us a call today. (303)443-0848

About the Author

Along with her almost 25 years in practice in non-surgical orthopedics, and her Stanford-affiliated Fellowship in Sports and Spine Medicine, Dr. Yurth has received her American Board of Anti-Aging/Regenerative Medicine (ABAARM) Board Certification from the American Academy of Anti-Aging Medicine (A4M), has completed her Fellowship in Anti-Aging and Regenerative Medicine (FAARM) and her Advanced Fellowship in Anti-Aging, Regenerative and Functional Medicine (FAARFM) also through A4M. She has also completed an independent fellowship in Epigenetic and Human Potential Medicine and is now part of the nation's very first cohort of Certified Peptide Specialiist through A4M. Dr. Yurth is an inaugural member of the International Peptide Society (IPS) and is an IPS/A4M faculty member and lecturer.